Association of MDM2 T309G (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population.

Autor:	Sivonova MK; Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic monika.kmetova.sivonova@uniba.sk., Jurecekova J; Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic., Kaplan P; Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic., Hives M; Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic., Grendar M; Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic., Tomascova A; Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic., Dusenka R; Department of Urology, Comenius University in Bratislava, Jessenius Faculty of Medicine and UHM, Martin, Slovak Republic., Drobkova H; Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic., Evin D; Department of Medical Biochemistry, Comenius University in Bratislava, Jessenius Faculty of Medicine, Martin, Slovak Republic.; Department of Nuclear Medicine, Comenius University in Bratislava, Jessenius Faculty of Medicine and UHM, Martin, Slovak Republic., Kliment J; Department of Urology, Comenius University in Bratislava, Jessenius Faculty of Medicine and UHM, Martin, Slovak Republic.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2020 Nov; Vol. 40 (11), pp. 6257-6264.
DOI:	10.21873/anticanres.14646
Abstrakt:	Background/aim: The aim of this study was to evaluate the relationship between MDM2 T309G polymorphism and prostate cancer risk in the Slovak population and the association of this polymorphism with MDM2 expression and clinicopathological features. Materials and Methods: The MDM2 T309G polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis in 506 prostate cancer patients and 592 controls. Quantitative real-time (RT)-PCR and western blot analysis were applied to examine MDM2 expression in 47 prostate cancer tissues and 43 benign prostatic hyperplasia (BPH) tissues. Results: A decreased risk of prostate cancer in men carrying the GG genotype in comparison with the TT genotype was found. A decrease in the relative MDM2 mRNA and protein levels was found in prostate cancer tissues among patients with the MDM2 GG genotype. Conclusion: There is a potentially protective effect of the MDM2 GG genotype on the risk of prostate cancer in the Slovak male population. (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu